|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-12-8
|
|
pubmed:abstractText |
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system probably mediated by Th1 lymphocytes. IFN-beta is an established therapy for relapsing MS patients, although the mechanisms underlying its efficacy are yet to be well characterized. We determined IL-2 production, CD25 expression and T-cell proliferation from relapsing-remitting MS patients before and three months after starting therapy. A decrease in the percentage of CD80-induced IL-2-producing cells was observed after in vivo IFN-beta treatment. These data support that one of the immunomodulatory effects of IFN-beta treatment in MS may be a limitation of the autoimmune response modifying the CD80:CD28/CTLA-4 pathway.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD28,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD80,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation,
http://linkedlifedata.com/resource/pubmed/chemical/CTLA-4 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/CTLA4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1352-4585
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
630-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15584487-Adjuvants, Immunologic,
pubmed-meshheading:15584487-Adult,
pubmed-meshheading:15584487-Animals,
pubmed-meshheading:15584487-Antigens, CD,
pubmed-meshheading:15584487-Antigens, CD28,
pubmed-meshheading:15584487-Antigens, CD80,
pubmed-meshheading:15584487-Antigens, Differentiation,
pubmed-meshheading:15584487-CTLA-4 Antigen,
pubmed-meshheading:15584487-Cell Division,
pubmed-meshheading:15584487-Cell Line, Tumor,
pubmed-meshheading:15584487-Female,
pubmed-meshheading:15584487-Humans,
pubmed-meshheading:15584487-Interferon-beta,
pubmed-meshheading:15584487-Interleukin-2,
pubmed-meshheading:15584487-Male,
pubmed-meshheading:15584487-Mastocytoma,
pubmed-meshheading:15584487-Middle Aged,
pubmed-meshheading:15584487-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:15584487-T-Lymphocytes,
pubmed-meshheading:15584487-Up-Regulation
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis.
|
|
pubmed:affiliation |
Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. cespejo@vhebron.net
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
